BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 21825287)

  • 21. Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification.
    Esterly JS; Wagner J; McLaughlin MM; Postelnick MJ; Qi C; Scheetz MH
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4885-90. PubMed ID: 22777044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Risk factors and resistance patterns of invasive
    Ge YL; Shan QW; Qiu Y; Zhou SP; Cheng YB; Wang F; Yang JW; Wan CM; Zhu Y; Xu Y; Chen MX; Lin DJ; Zhu CH; Zeng M
    Zhonghua Er Ke Za Zhi; 2022 Aug; 60(8):762-768. PubMed ID: 35922185
    [No Abstract]   [Full Text] [Related]  

  • 23. Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.
    Jain M; Sharma A; Sen MK; Rani V; Gaind R; Suri JC
    Microb Pathog; 2019 Mar; 128():75-81. PubMed ID: 30562602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes of children with carbapenem-resistant Acinetobacter baumannii bacteremia.
    Vandepitte WP; Berge J; Andersson R
    J Med Assoc Thai; 2014 Nov; 97 Suppl 11():S129-39. PubMed ID: 25509707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
    Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
    Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections.
    Song JY; Cheong HJ; Choi WS; Heo JY; Noh JY; Kim WJ
    J Med Microbiol; 2011 May; 60(Pt 5):605-611. PubMed ID: 21233298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii.
    Sheng WH; Liao CH; Lauderdale TL; Ko WC; Chen YS; Liu JW; Lau YJ; Wang LH; Liu KS; Tsai TY; Lin SY; Hsu MS; Hsu LY; Chang SC
    Int J Infect Dis; 2010 Sep; 14(9):e764-9. PubMed ID: 20646946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.
    Zheng YL; Wan YF; Zhou LY; Ye ML; Liu S; Xu CQ; He YQ; Chen JH
    Am J Infect Control; 2013 Jul; 41(7):e59-63. PubMed ID: 23523521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for occurrence and 30-day mortality for carbapenem-resistant Acinetobacter baumannii bacteremia in an intensive care unit.
    Kim SY; Jung JY; Kang YA; Lim JE; Kim EY; Lee SK; Park SC; Chung KS; Park BH; Kim YS; Kim SK; Chang J; Park MS
    J Korean Med Sci; 2012 Aug; 27(8):939-47. PubMed ID: 22876063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia.
    Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Peterson LE; Musser JM
    J Infect; 2014 Sep; 69(3):216-25. PubMed ID: 24841135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case-control study.
    Henig O; Weber G; Hoshen MB; Paul M; German L; Neuberger A; Gluzman I; Berlin A; Shapira C; Balicer RD
    Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):2063-8. PubMed ID: 26205665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.
    Garnacho-Montero J; Amaya-Villar R; Ferrándiz-Millón C; Díaz-Martín A; López-Sánchez JM; Gutiérrez-Pizarraya A
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):769-77. PubMed ID: 25865094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidrug resistant and extensively drug resistant Acinetobacter baumannii hospital infection associated with high mortality: a retrospective study in the pediatric intensive care unit.
    Shi J; Sun T; Cui Y; Wang C; Wang F; Zhou Y; Miao H; Shan Y; Zhang Y
    BMC Infect Dis; 2020 Aug; 20(1):597. PubMed ID: 32787942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter?
    Tuon FF; Rymsza AM; Penteado-Filho SR; Pilonetto M; Arend LN; Levin AS
    J Infect; 2011 Mar; 62(3):246-9. PubMed ID: 21256151
    [No Abstract]   [Full Text] [Related]  

  • 35. Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy.
    Kim YJ; Kim SI; Hong KW; Kim YR; Park YJ; Kang MW
    J Korean Med Sci; 2012 May; 27(5):471-5. PubMed ID: 22563209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of antibiotic exposure on occurrence of nosocomial carbapenem-resistant Acinetobacter baumannii infection: a case control study.
    Chusri S; Silpapojakul K; McNeil E; Singkhamanan K; Chongsuvivatwong V
    J Infect Chemother; 2015 Feb; 21(2):90-5. PubMed ID: 25454216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characteristics and outcomes of community and hospital-acquired Acinetobacter baumannii bacteremia.
    Chusri S; Chongsuvivatwong V; Silpapojakul K; Singkhamanan K; Hortiwakul T; Charernmak B; Doi Y
    J Microbiol Immunol Infect; 2019 Oct; 52(5):796-806. PubMed ID: 31031096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection.
    Jamulitrat S; Arunpan P; Phainuphong P
    J Med Assoc Thai; 2009 Mar; 92(3):413-9. PubMed ID: 19301737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia.
    Lemos EV; de la Hoz FP; Alvis N; Einarson TR; Quevedo E; Castañeda C; Leon Y; Amado C; Cañon O; Kawai K
    Clin Microbiol Infect; 2014 Feb; 20(2):174-80. PubMed ID: 23668595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality.
    Hernández-Torres A; García-Vázquez E; Gómez J; Canteras M; Ruiz J; Yagüe G
    Med Clin (Barc); 2012 May; 138(15):650-5. PubMed ID: 22093403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.